GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » Days Sales Outstanding

AMEUF (Anteris Technologies) Days Sales Outstanding : 94.17 (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies Days Sales Outstanding?

Anteris Technologies's average Accounts Receivable for the six months ended in Dec. 2024 was $0.66 Mil. Anteris Technologies's Revenue for the six months ended in Dec. 2024 was $1.28 Mil. Hence, Anteris Technologies's Days Sales Outstanding for the six months ended in Dec. 2024 was 94.17.

The historical rank and industry rank for Anteris Technologies's Days Sales Outstanding or its related term are showing as below:

AMEUF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.63   Med: 42.76   Max: 76.38
Current: 76.38

During the past 13 years, Anteris Technologies's highest Days Sales Outstanding was 76.38. The lowest was 26.63. And the median was 42.76.

AMEUF's Days Sales Outstanding is ranked worse than
61.6% of 810 companies
in the Medical Devices & Instruments industry
Industry Median: 66.455 vs AMEUF: 76.38

Anteris Technologies's Days Sales Outstanding increased from Dec. 2023 (87.00) to Dec. 2024 (94.17).


Anteris Technologies Days Sales Outstanding Historical Data

The historical data trend for Anteris Technologies's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies Days Sales Outstanding Chart

Anteris Technologies Annual Data
Trend Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.76 27.66 37.87 55.32 41.46

Anteris Technologies Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 188.11 71.89 87.00 97.67 94.17

Competitive Comparison of Anteris Technologies's Days Sales Outstanding

For the Medical Devices subindustry, Anteris Technologies's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's Days Sales Outstanding falls into.


;
;

Anteris Technologies Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Anteris Technologies's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0.406 + 0.208) / 2 ) / 2.703*365
=0.307 / 2.703*365
=41.46

Anteris Technologies's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding (Q: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2024 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (1.115 + 0.208) / 2 ) / 1.282*365 / 2
=0.6615 / 1.282*365 / 2
=94.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anteris Technologies  (OTCPK:AMEUF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Anteris Technologies Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies Business Description

Traded in Other Exchanges
Address
9 Sherwood Road, Level 3, Suite 302, Toowong, QLD, AUS, 4066
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.